Moneycontrol Be a Pro
Get App
Last Updated : Mar 02, 2017 01:32 PM IST | Source:

Hold Merck; target of Rs 1020: Centrum

Centrum recommended hold rating on Merck with a target price of Rs 1020 in its research report dated March 01, 2017.

  • bselive
  • nselive
Todays L/H

Centrum's research report on Merck

Merck’s pharma segment (75% of revenues) grew 9% YoY to Rs 1.89bn from Rs 1.73bn. Merck is a pioneer in the vitamin segment, with three major brands Neurobion, Polybion and Evion. Evion does not fall under the National List of Essential Medicines (NLEM) and is hence its price hasn’t been capped.


We maintain Hold rating on Merck, with a TP of Rs 1,020 (earlier Rs 990) based on 14x December’18E EPS of Rs 72.7. Merck’s pharma segment (75% of revenues) reported 9% YoY growth in revenues, while its chemical segment (25% of revenues) posted a 4% decline, affecting overall sales growth.

For all recommendations, click here

The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Mar 2, 2017 01:32 pm
Follow us on
Available On